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1. Introduction 
Vesicular fragments of sarcoplasmic reticulum (SR), 
isolated from skeletal muscle, rapidly accumulate Ca*+ 
[l-3] in the presence of adenosine triphosphate 
(ATP). Owing to its high specific activity, SR con- 
stitutes an outstanding system for studies on ion 
interactions with biological membranes [4,5] , The 
kinetic behavior of Ca” uptake and the simultaneous 
occurrence of ATP hydrolysis suggest hat Ca2+ is 
transported into the inner space of the membrane 
vesicles [4]. The resulting concentration gradient is 
made energetically possible through hydrolysis of ATP 
[6] . It was also shown that SR has a significant cation 
binding capacity, in the absence of ATP [7, 81. 
Although these binding sites have an affinity for Ca’+ 
lower than that displayed by SR [9, lo] in the 
presence of ATP, it was proposed that part or all of 
the ATP-dependent Ca2+ accumulation may be due to 
simple binding of Ca2+ rather than resulting from ionic 
gradients [7,8]. 
This problem may be clarified by the use of 
ionophores. We have now found that low concentrations 
of X-537 A, a Ca2+ ionophorous antibiotic, when 
added to SR suspensions after the occurrence of Ca2+ 
accumulation, produce a total release of the previously 
accumulated Ca”. Our results are consistent with the 
equilibration of the Ca ionic gradients, mediated by 
the ionophore X-537 A. 
* Permanent address: Mellon Institute, Carnegie Mellon 
University, Pittsburgh, Pa. 19213, USA. 
2. Materials and methods 
SR was prepared by differential centrifugation of 
homogenized skeletal muscle, obtained from rabbit 
hind legs [ 113. Ca2+ movements were followed by 
measuring the light absorption changes undergone by 
murexide, a metallochromic indicator of calcium ion 
concentration [ 121. The optical changes of the 
indicator were monitored by a dual wavelength 
(540-507 nm) spectrophotometer [131 as described 
previously [ 141 . 
Reaction mixtures contained 20 mM Tris-maleate 
pH 6.8,50 mM KCl, 10 mM MgCl,, 120 I.IM total 
Ca2+, 100 PM murexide and indicated amounts of 
sarcoplasmic reticulum. The temperature of the 
reaction medium was 24”. ATPase activity was 
measured as described before [ 151 and protein was 
estimated by the Folin method. 
Crystalline Na-ATP (lot lOOC-7620) containing 
less than 8 ppm Ca contaminant was purchased from 
Sigma, St. Louis, MO.; murexide (ammonium purpurate) 
from K and K Chemicals, Plainview, N.Y.; valinomycin 
from Calbiochem. San Diego, Calif. X-537 A was a 
gift from Drs. J. Berger and H.H. Leher of Hoffman- 
LaRoche, and carbonyl cyanide-p-trifluoromethoxy 
phenylhydrazone (FCCP) from Dr. P. Heitler of du 
Pont. 
3. Results and discussion 
X-537 A is an antibiotic obtained from an 
unidentified streptomyces [ 161, which is effective 
against coccidial infection in chickens [ 171. The 
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molecule is a substituted salicylic acid, with a side 
chain containing a high proportion of oxygen [ 181 
(fig. 1). 
X-537 A is known to form lipophilic complexes 
with monovalent cations thereby increasing the per- 
meability of natural and artificial membranes to Na+, 
K’, Cs+ and H+ in analogy to such ionophores as 
nigericin and monensin [ 19,201 . In addition, X-537 A 
is able to complex divalent cations. In fact, X-ray 
studies of the barium salt of X-537 A have shown that 
two antibiotic molecules encircle the barium ion and 
the water of crystallization, the antibiotic being 
stabilized through coordination to .the metal ion and 
perhaps hydrogen bonding to water [21]. The 
resulting complex has a spherical shape, with the 
oxygen atoms buried inside to form a hydrophilic 
pocket for the cation and its water. The exterior is 
hydrophobic and results in a low solubility of the salt 
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Fig. 3. ATP-dependent Cap accumulation by SR. Ca* release 
is caused by X-537 A, but not by valinomycin or FCCP. SR 
was present at a concentration of 0.42 mg/ml. 
in water and a high solubility in organic solvents. 
These properties would render X-537 A a carrier of 
Ca2+ through biological membranes containing 
hydrophobic regions. We have recently observed that 
X-537 A increases Ca” fluxes through isolated mito- 
chondria, red cells and plasma membranes of isolated 
myoblasts [22] . For this reason, we have performed 
experiments to test the effect of X-537 A on the per- 
meability of SR to Ca2+. 
Fig. 2A shows a calibration of the system in the 
absence of SR. The addition of Ca2+ produces a 
decrease in light absorbance due to the formation of a 
Fig. 2. A, B and C. A) Light absorbancy changes undergone by murexide on addition of CaC12, ATP and X-537 A in the experi- 
mental medium devoid of SR. B and C) ATP-dependent Ca* accumulation by SR (0.36 mg/ml) and subsequent release induced 
by X-537 A. 
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Ca-murexide complex which exhibits lower absorb- 
ance at 540 nm. This effect was quantitatively 
reproduced by successive additions of Ca’+, indicating 
that the observed absorbancy changes were a linear 
function of the Ca*’ concentration. The additions of 
ATP and X-537 A, in the absence of SR, do not 
produce any significant changes and, in this mixture, 
their competition with murexide for calcium ion does 
not result in any absorbance changes. 
The addition of ATP to a reaction mixture con- 
taining SR (figs. 2B and 2C) is followed by a burst of 
Ca*’ accumulation by the vesicles, reaching a steady 
state level of 180 pmoles Ca*+/mg membrane protein. 
Figs. 2B and 2C also show that a rapid Ca*+ efflux is 
produced by the subsequent addition of X-537 A to 
the Ca*’ loaded SR vesicles. The resulting reduction 
of steady state levels is proportional to the concentra- 
tion of the ionophorous antibiotic. A 20 PM concen- 
tration of X-537 A produces a release of all the 
accumulated Ca*‘. 
Fig. 3 shows that other ionophores such as 
valinomycin and FCCP, which are known to increase 
the membrane permeability to K’ and H+, respectively 
[ 19,201, do not alter Ca*+ accumulation by SR, even 
if used in very high concentrations. Similarly, the 
addition of either nigericin (25 PM) or gramicidin 
(25 PM) was without effect (result not shown). The 
lack of effect on Ca2+ accumulation by such mono- 
valent cation carriers indicates that the action of 
X-537 A on SR is related to its specific ability to form 
lipophilic complexes with divalent cations and there- 
fore to increase the membrane permeability to Ca*‘. 
It may be ruled out that X-537 A may affect Ca*+ 
movements in SR through different mechanisms. The 
possibility that X-537 A interacts with nonspecific 
binding sites for Ca*+ can be excluded on the basis of 
4sCa2+ measurements howing that, in the absence of 
ATP, the amounts of CaB bound to SR was not 
affected by the presence of 20 PM X-537 A. More- 
over, X-537 A could interact with some specific 
component of the pump itself; Ca2+ uptake by SR is a 
rapid phenomena which is accompanied by a rapid 
burst of the ATPase activity. When the Ca*’ has been 
accumulated inside the vesicles, ATPase activity 
returns to the same level present before the addition 
of Ca*+ [4,5]. W e f ound that Ca*+ activated ATPase 
was not inhibited by X-537 A but instead stimulated 
and the initial burst was continued for long periods of 
time. No ATPase stimulation was observed in the 
presence of ethylene glycol @-aminoethyl ether)- 
N, N’-tetracetic acid (EGTA). On the other hand, the 
effect of X-537 A on membrane permeability to 
cations is also observed in a variety of natural and 
artificial membranes [ 19,201 , not all of which 
possess imilar Ca*+ binding sites or Ca*+ pump. 
To conclude, the effect of X-537 A on SR is best 
explained by an increase in membrane permeability 
induced by the antibiotic, and a consequent equilibra- 
tion of the Ca*’ gradient created by the pump. The 
reduced steady states obtained in the presence of the 
ionophore reflect levels at which the rates of passive 
efflux equal the rates of active transport. 
X-537 A, in addition to offering insights into the 
mechanism of Ca2+ accumulation by SR, promises to 
be a very useful tool in the study of several biological 
control mechanisms where Ca*+ concentration 
gradients in cells or subcellular organelles are a 
limiting factor. 
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